Martin Dietrich, MD, PhD

Articles

Discussing Biomarker Testing with Patients

September 20th 2022

Ellen Ball, ANP-FNP, provides a look at the conversations she has with patients when discussing their options for genetic testing in breast cancer.

Use of Liquid Biopsies in Breast Cancer

September 20th 2022

Drs McKenzie and Vidal debate the use of liquid biopsies in breast cancer.

Challenges of Biomarker Testing in Breast Cancer

September 12th 2022

Dr Gregory Vidal describes the approaches for biomarker testing in breast cancer and the challenges clinicians face.

Biomarker Testing Interpretation in Breast and Lung Cancer

September 12th 2022

Andrew McKenzie, PhD, details how to interpret the results of biomarker testing in breast cancer and lung cancer.

Choosing a Molecular Testing Panel for Solid Tumors

September 6th 2022

Dr Andrew McKenzie explains how to choose the appropriate molecular testing for a patient.

Currently Targetable Mutations in Lung and Breast Cancer

September 6th 2022

Drs Dietrich and Vidal discuss the currently known targetable actionable mutations in breast cancer and lung cancer.

Clinical Scenario: A 44-Year-Woman with Metastatic Breast Cancer

September 3rd 2022

Dr Martin Dietrich presents a second clinical scenario of a 44-year-old woman with metastatic, highly-aggressive breast cancer.

PD-L1 Expression and IO Therapy in Lung and Breast Cancer

September 3rd 2022

A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.

Using Molecular Testing to Guide Treatment Decisions

August 29th 2022

Gregory Vidal, MD, PhD, highlights the benefits and drawbacks of the available biomarker testing options and how the results guide treatment decision-making.

Available Molecular Tests for Solid Tumors

August 29th 2022

Andrew McKenzie, PhD, provides an overview of the various forms of molecular testing available for identifying actionable alterations in breast and lung cancer.

Unmet Needs and Future Directions in the Management of CIM

July 22nd 2022

Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.

An Overview of Trilaciclib Safety and Patient QOL Outcomes

July 22nd 2022

Focusing the discussion on the clinical trials that led to the FDA approval of trilaciclib, experts in ES-SCLC share key insights into the drug’s safety and its effect on patient quality of life.

Trilaciclib Efficacy in the Prevention of CIM in ES-SCLC

July 15th 2022

Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.

Myeloprotective Benefit of CDK4/6 Inhibition in ES-SCLC

July 15th 2022

Edgardo Santos, MD, FACP, and Martin Dietrich, MD, PhD, share insights into the mechanism of action of CDK4/6 inhibitors for the prevention of myelosuppression in ES-SCLC.

Prophylactic Approaches to the Management of CIM in ES-SCLC

July 8th 2022

Expert panelists review considerations in the prophylactic treatment of chemotherapy-induced myelosuppression with special attention paid to unmet needs related to the use of G-CSF and ESAs.

An Overview of Chemotherapy-Induced Myelosuppression in ES-SCLC

July 8th 2022

Two leaders in the management of ES-SCLC provide an overview of chemotherapy-induced myelosuppression including key risk factors and its effect on patient outcomes.

Closing Expert Perspectives on Treatment in Advanced NSCLC

June 2nd 2022

Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.

Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape

June 2nd 2022

Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.

Recent Advances in Treatment of ROS1-Rearranged NSCLC

May 25th 2022

Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.

Updates in Treatment of NSCLC with ALK Rearrangements

May 25th 2022

Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.